TickerFacts.

Company research / ANAB

Anaptysbio, Inc (ANAB)

Build a valuation ↗↓ Download CSV

SEC name ANAPTYSBIO, INC · CIK 0001370053 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Jun 30

For the year ended 2025-12-31, Anaptysbio, Inc reported revenue of $234.60M. Revenue grew 157.0% from the prior annual period. Over the twelve months to 2026-03-31, revenue was $232.39M.

Key ratios (year ended 2025-12-31)

20.4%
Operating margin
-5.6%
Net margin
-35.6%
Return on year-end equity
157.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-03-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-03-31		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$232.39M$234.60M$91.28M$17.16M$10.29M$63.17M$75.00M$8.00M$5.00M$10.00M$16.68M
R&D Expense$128.78M$135.97M$163.84M$132.28M$88.80M$98.50M$80.03M$99.34M$56.20M$29.44M$15.42M
Operating Income$40.80M$47.90M-$114.95M-$164.41M-$115.15M-$56.81M-$23.88M-$107.43M-$66.72M-$28.78M-$3.02M
Depreciation & Amortization$543.0K$559.0K$606.0K$652.0K$675.0K$619.0K$559.0K$514.0K$315.0K$183.0K$233.0K
EBITDA$41.34M$48.45M-$114.34M-$163.76M-$114.48M-$56.20M-$23.32M-$106.92M-$66.41M-$28.60M-$2.79M
Net Income-$26.79M-$13.23M-$145.23M-$163.62M-$128.72M-$57.80M-$19.93M-$97.34M-$61.66M-$30.07M-$4.26M
EPS (Diluted)n/a-$0.46-$5.12-$6.08-$4.57-$2.11-$0.73-$3.60-$2.50-$1.52-$1.62
Total Assets$329.68M$364.39M$483.83M$452.39M$610.38M$643.07M$416.55M$435.20M$509.00M$329.36M$62.18M
Shareholders' Equity$12.75M$37.21M$70.87M$88.10M$262.10M$356.43M$396.73M$405.01M$486.37M$307.58M-$38.25M
Cash & Equivalents$248.47M$238.20M$123.08M$35.97M$71.31M$495.73M$250.46M$171.02M$113.60M$81.19M$51.23M
Operating Cash Flow$4.48M$19.70M-$135.34M-$120.80M-$73.59M-$45.92M-$14.16M-$69.52M-$48.51M-$19.44M-$9.03M
Capital Expenditures$69.0K$87.0K$358.0K$807.0K$358.0K$1.37M$569.0K$805.0K$1.06M$290.0K$50.0K
Free Cash Flow$4.41M$19.61M-$135.69M-$121.61M-$73.95M-$47.29M-$14.73M-$70.32M-$49.57M-$19.73M-$9.08M
Share Repurchases$64.20M$68.63M$456.0K$50.00M$0$0n/an/a$0$0$1.0K
Shares Outstanding29.03M28.02M30.47M26.60M28.51M27.65M27.36M27.25M26.92M23.79M2.65M
Weighted Average Diluted Sharesn/a28.76M28.38M26.92M28.16M27.43M27.30M27.06Mn/an/an/a
EPS (Basic)n/a-$0.46-$5.12-$6.08-$4.57-$2.11-$0.73-$3.60-$2.50-$1.52-$1.62

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView